NERV MINERVA NEUROSCIENCES

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL.

The Citizens Life Sciences Conference

Format:Company presentation
Day/Time: Tuesday, March 10 at 9:35 AM ET
Webcast:
  

If you are interested in meeting with the Minerva team during the conference, please reach out to your Citizens Bank representative.

A replay of the presentation will be available on the Company's Investors & Media webpage for ninety days following the event.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s .

Contacts:

Investor inquiries:

Frederick Ahlholm

Chief Financial Officer

Minerva Neurosciences, Inc.

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577



EN
04/03/2026

Underlying

NERVMINERVA NEUROSCIENCES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINERVA NEUROSCIENCES

 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences to Participate in The Citizens Life Sciences Con...

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL. The Citizens Life Sciences ConferenceFormat:Company presentationDay/Time: Tuesday, March 10 at 9:35 AM ...

2h / 59m 1 EN
 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidon...

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Prof...

January 26, 2026 1 EN
 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Boar...

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company successfully raising up to $200 million in a private ...

November 19, 2025 1 EN
 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and...

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates  On October 23, 2025, the Company received $80 million in gross proceeds in a , before deducting fees and other expenses. The financing includes an initial upfront funding of ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences Announces Financing of up to $200 Million to Adv...

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved   Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission.Further $40 million proceeds may be received in connection with cas...

October 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch